## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.43 indicates fundamental undervaluation. Quality metrics strong (ROE 37%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-6.1% MRS), overbought RSI (79).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($81.23)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Solventum stock rating upgraded to Buy at BTIG on improved execution By Investing.com**
- Source: Investing.com Nigeria | 20251202T122600 | Bullish | Relevance: 100%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and overcoming initial challenges faster than expected for the healthcare spin-out. The upgrade reflects optimism about Solventum's top-line growth and increased margins, supported by recent divestitures and acquisitions. Despite a recent EPS miss, the company's strategic moves, including the acquisition of Acera Surgical and a share repurchase program, are expected to drive future growth and shareholder value.

**2. Solventum stock rating upgraded to Buy at BTIG on improved execution**
- Source: Investing.com | 20251202T062500 | Bullish | Relevance: 100%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and a stronger outlook for 2026. This upgrade reflects the company's faster-than-expected resolution of initial challenges, debt reduction through divestiture, and consistent performance against guidance, despite a recent EPS miss. The company also announced plans to acquire Acera Surgical and a $1 billion share repurchase program.

**3. (SOLV) Volatility Zones as Tactical Triggers**
- Source: Stock Traders Daily | 20251203T211000 | Neutral | Relevance: 100%
- This article provides a detailed AI-driven analysis for Solventum Corporation (NASDAQ: SOLV), highlighting neutral near-term readings and potentially stalling mid-term strong sentiment. It outlines three distinct institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis for support and resistance levels.

**4. Solventum stock rating upgraded to Buy at BTIG on improved execution**
- Source: Investing.com India | 20251202T165600 | Bullish | Relevance: 100%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and increased investor confidence following the company's divestiture of its Purification & Filtration business and consistent performance. The upgrade reflects BTIG's positive outlook on Solventum's top-line growth and expected margin increases, supported by 6 analysts revising earnings upwards. Despite a recent earnings miss in Q3 2025, Solventum's acquisition of Acera Surgical and a $1 billion share repurchase program signal strategic moves for market presence and shareholder value.

**5. Solventum stock rating upgraded to Buy at BTIG on improved execution**
- Source: Investing.com Nigeria | 20251202T122600 | Bullish | Relevance: 100%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and a positive outlook for the healthcare spin-out. The upgrade reflects Solventum's success in overcoming initial challenges, reducing debt through a business divestiture, and its consistent performance against guidance. The company's recent acquisition plans and share repurchase program are also highlighted as positive strategic moves.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |
| 2025-11-10 | UBS | $79 | $77 | +3% |
| 2025-11-07 | Piper Sandler | $98 | $94 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |
| 2025-11-10 | UBS | main | Neutral |
| 2025-11-07 | Piper Sandler | main | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.43 suggests fair value with growth premium. Forward P/E 13.4x stretched relative to 6% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.43 |
| Forward P/E | 13.4 |
| Current P/E | 14.2 |
| YoY Growth | 5.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 13.0% to 6.9% (-6.1% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 (-0.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 9.0% shows strong absolute momentum above own 20MA. Outperforming sector by 7.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.76), confirming momentum. RSI overbought at 79, risk of mean reversion. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.90% (CS: 91) | Strong |
| RSI_14 | 78.8 | Overbought |
| MACD Histogram | 0.76 | Bullish |
| vs SMA20 | 1.090x | Above |
| vs SMA50 | 1.148x | Above |
| vs SMA200 | 1.163x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $85.25
- **Stop Loss:** $81.23 (4.7% risk)
- **Target:** $93.29 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 236
- **Position Value:** $20,119.00
- **Portfolio %:** 20.12%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*